Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Over 4 Years of Safety and Efficacy with Voxelotor Treatment for Patients with Sickle Cell Disease: Updated Results from an Open-Label Extension of the Phase 3 HOPE Trial

Maureen Okam Achebe, Hoda MA Hassab, Salam Al-Kindi, Clark Brown, Paul Telfer, Bart J. Biemond, Thokozeni Lipato, Mark Davis, Sarah Gray, Victor R. Gordeuk

Blood (2023) 142 (Supplement 1): 2527.

https://doi.org/10.1182/blood-2023-188616

Published: 2023

Journal Articles

Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial

Maureen Achebe, Hoda Hassab, Salam Alkindi, R. Clark Clark Brown, Paul Telfer, Bart J. Biemond, Victor R. Gordeuk, Thokozeni Lipato, Margaret Tonda, Sarah Gray, Joanna Howard

Blood (2021) 138 (Supplement 1): 3114.

https://doi.org/10.1182/blood-2021-153582

Published: 2021

Journal Articles

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

Elliott Vichinsky, MD, Victor R. Gordeuk, MD, Paul Telfer, DM, FRCP, Adlette Inati, MD FAAP, Margaret Tonda, PharmD, Sarah Gray, PhD, Irene Agodoa, MD, Kenneth I. Ataga, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140863

Published: 2020

Journal Articles

Improvement in the Clinical Global Impression of Change with Voxelotor in Patients with Sickle Cell Disease in the Phase 3 HOPE Trial

Wally R Smith, MD, Jane S. Hankins, MD MS, Miguel R Abboud, MD, Ze Cong, PhD, Jonathan Sorof, MD, Sarah Gray, PhD, Carolyn Hoppe, MD, Paul Telfer, DM, FRCP

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-137121

Published: 2020

Journal Articles

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Jo Howard, MBBChir, MRCP, FRCPath, Kenneth I. Ataga, MD, R. Clark Brown, MD PhD, Maureen Achebe, MD MPH, Videlis Nduba, MD, Amal El-Beshlawy, MD, Hoda Hassab, MD, Irene Agodoa, MD, Margaret Tonda, PharmD, Sarah Gray, PhD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Elliott Vichinsky, MD

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-140553

Published: 2020

NARROW

Over 4 Years of Safety and Efficacy with Voxelotor Treatment for Patients with Sickle Cell Disease: Updated Results from an Open-Label Extension of the Phase 3 HOPE Trial

Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

Improvement in the Clinical Global Impression of Change with Voxelotor in Patients with Sickle Cell Disease in the Phase 3 HOPE Trial

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Email alerts

ASH Publications

American Society of Hematology

Over 4 Years of Safety and Efficacy with Voxelotor Treatment for Patients with Sickle Cell Disease: Updated Results from an Open-Label Extension of the Phase 3 HOPE Trial

Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial

Higher Hemoglobin Levels Achieved with Voxelotor Are Associated with Lower Vaso-occlusive Crisis Incidence: 72-Week Analysis from the HOPE Study

Improvement in the Clinical Global Impression of Change with Voxelotor in Patients with Sickle Cell Disease in the Phase 3 HOPE Trial

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only